0001563665 Harvard Apparatus Regenerative Technology, Inc. false --12-31 Q1 2026 0.01 0.01 60,000,000 60,000,000 17,580,744 17,580,744 17,580,744 17,580,744 2 0 0 0 898,622 5.33 4 10 3 0 0 2 2 false false false false Certain general and administrative costs (including executive compensation, corporate legal fees, audit fees, investor relations, and insurance) are shared across both segments. For internal reporting purposes, such costs are allocated to each segment based on an estimate of the proportion of management time and corporate resources utilized by each segment. Costs directly attributable to a segment are charged directly to that segment. For the three months ended March 31, 2026 and 2025, the Regenerative Biotech segment bore substantially all general and administrative expense, as the Consumer Health Products segment incurred minimal shared corporate overhead. “Other segment items” for the Regenerative Biotech segment consists primarily of net interest income earned on money market balances and other miscellaneous income, partially offset by interest expense on insurance premium financing. For the Consumer Health Products segment, other segment items consist of foreign currency transaction effects and other minor income items. The other segment items line represents the arithmetic difference between segment revenues, less the significant expense categories disclosed above, and the reported segment net loss, in accordance with ASC 280-10-50-26B. 00015636652026-01-012026-03-31 xbrli:shares 00015636652026-05-04 thunderdome:item iso4217:USD 00015636652026-03-31 00015636652025-12-31 iso4217:USDxbrli:shares 00015636652025-01-012025-03-31 0001563665us-gaap:CommonStockMember2025-12-31 0001563665us-gaap:AdditionalPaidInCapitalMember2025-12-31 0001563665us-gaap:RetainedEarningsMember2025-12-31 0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-31 0001563665us-gaap:CommonStockMember2026-01-012026-03-31 0001563665us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31 0001563665us-gaap:RetainedEarningsMember2026-01-012026-03-31 0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-31 0001563665us-gaap:CommonStockMember2026-03-31 0001563665us-gaap:AdditionalPaidInCapitalMember2026-03-31 0001563665us-gaap:RetainedEarningsMember2026-03-31 0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-31 0001563665us-gaap:CommonStockMember2024-12-31 0001563665us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001563665us-gaap:RetainedEarningsMember2024-12-31 0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31 00015636652024-12-31 0001563665us-gaap:CommonStockMember2025-01-012025-03-31 0001563665us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31 0001563665us-gaap:RetainedEarningsMember2025-01-012025-03-31 0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31 0001563665us-gaap:CommonStockMember2025-03-31 0001563665us-gaap:AdditionalPaidInCapitalMember2025-03-31 0001563665us-gaap:RetainedEarningsMember2025-03-31 0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-31 00015636652025-03-31 0001563665hrgn:InsurancePremiumFinancingPayableMember2026-01-012026-03-31 0001563665hrgn:InsurancePremiumFinancingPayableMember2025-01-012025-03-31 xbrli:pure 00015636652024-07-31 0001563665hrgn:ClinicalActivityTrialsMember2026-01-012026-03-31 0001563665hrgn:ClinicalActivityTrialsMember2026-03-31 0001563665hrgn:OtherDepositsMember2026-03-31 utr:Y 0001563665us-gaap:ComputerEquipmentMember2026-03-31 0001563665hrgn:FurnitureMachineryAndEquipmentMembersrt:MinimumMember2026-03-31 0001563665hrgn:FurnitureMachineryAndEquipmentMembersrt:MaximumMember2026-03-31 0001563665us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhrgn:HealthRegenMember2026-01-012026-03-31 0001563665us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhrgn:HealthRegenMember2025-01-012025-03-31 0001563665us-gaap:PrivatePlacementMember2025-12-302025-12-30 0001563665us-gaap:PrivatePlacementMember2025-12-30 0001563665us-gaap:PrivatePlacementMember2025-07-112025-07-11 0001563665us-gaap:PrivatePlacementMember2025-07-11 0001563665hrgn:EquityIncentivePlanMember2026-01-012026-03-31 0001563665hrgn:EquityIncentivePlanMember2026-03-31 00015636652025-01-012025-12-31 0001563665hrgn:PerformanceBasedStockOptionsMemberhrgn:EquityIncentivePlanMember2026-03-31 0001563665hrgn:NonPerformanceBasedOptionsMemberhrgn:EquityIncentivePlanMember2026-03-31 0001563665hrgn:NonPerformanceBasedOptionsMemberhrgn:EquityIncentivePlanMember2026-01-012026-03-31 0001563665hrgn:ResearchAndDevelopmentMemberhrgn:EquityIncentivePlanMember2026-01-012026-03-31 0001563665hrgn:ResearchAndDevelopmentMemberhrgn:EquityIncentivePlanMember2025-01-012025-03-31 0001563665hrgn:GeneralAndAdministrativeMemberhrgn:EquityIncentivePlanMember2026-01-012026-03-31 0001563665hrgn:GeneralAndAdministrativeMemberhrgn:EquityIncentivePlanMember2025-01-012025-03-31 0001563665hrgn:EquityIncentivePlanMember2025-01-012025-03-31 utr:sqft 0001563665hrgn:HQOperatingLeaseAgreementMember2024-08-12 0001563665hrgn:ServicesAgreementWithBeijingQuarkmedTechnologyCoLtdMember2025-07-01 0001563665hrgn:ServicesAgreementWithBeijingQuarkmedTechnologyCoLtdMember2025-09-30 0001563665hrgn:ServicesAgreementWithBeijingQuarkmedTechnologyCoLtdMember2026-03-31 0001563665hrgn:InsurancePremiumFinancingPayableMember2025-11-30 0001563665hrgn:InsurancePremiumFinancingPayableMember2026-03-31 0001563665hrgn:HQOperatingLeaseAgreementMember2026-03-31 0001563665hrgn:ResearchAndDevelopmentMember2026-01-012026-03-31 0001563665hrgn:ResearchAndDevelopmentMember2025-01-012025-03-31 0001563665hrgn:GeneralAndAdministrativeMember2026-01-012026-03-31 0001563665hrgn:GeneralAndAdministrativeMember2025-01-012025-03-31 0001563665us-gaap:EmployeeStockOptionMember2026-01-012026-03-31 0001563665us-gaap:EmployeeStockOptionMember2025-01-012025-03-31 0001563665us-gaap:WarrantMember2026-01-012026-03-31 0001563665us-gaap:WarrantMember2025-01-012025-03-31 0001563665hrgn:RegenerativeBiotechMember2026-01-012026-03-31 0001563665hrgn:ConsumerHealthProductsMember2026-01-012026-03-31 0001563665hrgn:RegenerativeBiotechMember2025-01-012025-03-31 0001563665hrgn:ConsumerHealthProductsMember2025-01-012025-03-31 0001563665hrgn:RegenerativeBiotechMember2026-03-31 0001563665hrgn:RegenerativeBiotechMember2025-12-31 0001563665hrgn:ConsumerHealthProductsMember2026-03-31 0001563665hrgn:ConsumerHealthProductsMember2025-12-31 0001563665hrgn:TheBridgeNoteMemberus-gaap:SubsequentEventMember2026-05-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2026

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission file number 001-35853

Harvard Apparatus Regenerative Technology, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		45-5210462
(State or Other Jurisdiction of		(IRS Employer
Incorporation or Organization)		Identification No.)

84 October Hill Road, Suite 11, Holliston, MA		01746
(Address of Principal Executive Offices)		(Zip Code)

(774) 233-7300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒	Smaller reporting company ☒

	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of May 4, 2026, there were 17,580,744 shares of common stock, par value $0.01 per share, outstanding.

Table of Contents

Harvard Apparatus Regenerative Technology, Inc.

Form 10-Q

For the Quarter Ended March 31, 2026

INDEX

		Page
PART I-FINANCIAL INFORMATION		5

Item 1.	Condensed Consolidated Financial Statements	5

	Condensed Consolidated Balance Sheets	5

	Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	6

	Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)	7

	Condensed Consolidated Statements of Cash Flows (Unaudited)	8

	Notes to Unaudited Condensed Consolidated Financial Statements	9

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	27

Item 4.	Controls and Procedures	27

PART II-OTHER INFORMATION		28

Item 1.	Legal Proceedings	28

Item 1A.	Risk Factors	28

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28

Item 3.	Defaults Upon Senior Securities	28

Item 6.	Exhibits	28

SIGNATURES		30

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that relate to future events, our future operations or financial performance, or our plans, strategies and prospects. These statements are based on the beliefs and assumptions of our management team. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or performance, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates” or “intends” or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these identifying words. The forward-looking statements are based on projections prepared by, and are the responsibility of, our management team. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

● our ability to access debt and equity markets and raise additional capital when needed;

● plans and expectations that depend on our ability to continue as a going concern;

● the success of our collaborations, clinical trials and pre-clinical development efforts and programs, which success may not be achieved on a timely basis or at all;

● our ability to obtain and maintain regulatory approval for our implant products, bioreactors, scaffolds and other devices we pursue, including for the esophagus or airway, which approvals may not be obtained on a timely basis or at all;

● the number of patients who can be treated with our products;

● the amount and timing of costs associated with our development of implant products, bioreactors, scaffolds and other devices;

● our ability to comply with regulations and any changes in regulations;

● our ability to avoid or minimize unpredictable difficulties or delays in the development of new technology;

● the ability of our collaborators or other third parties we contract with, including with respect to conducting any clinical trial or pre-clinical development efforts, to devote sufficient time and resources to successfully carry out their duties or meet expected deadlines;

● our ability to implement our growth strategy;

● our ability to attract and retain qualified personnel and key employees and retain senior management;

● the availability and price of acceptable raw materials and components from third-party suppliers;

● the potential for liability exposure with respect to our products;

● our estimates regarding expenses, future revenue, capital requirements, cash runway and needs for additional financing;

● our ability to compete in the fields of regenerative medicine and bioengineering and in consumer health products, and the financial resources of our competitors;

● our financial performance;

Table of Contents

● the effects of the control our principal stockholders can exert based on holding a majority of voting power;

● our intellectual property rights and our ability to protect or enforce these rights, and the impact on our business, results and financial condition if we are unsuccessful in doing so; and

● our ability to address economic downturns and political and market conditions beyond our control and their potential to adversely affect our business, financial condition and results of operations, including, but not limited to, increasing our expenses and cost of capital and adversely impacting our supply chain.

These forward-looking statements are based on information available as of the date of this report, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Important factors could cause actual results, performance or achievements to differ materially from those indicated or implied by forward-looking statements such as those described under the caption “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K, in Part II, Item 1A of this Quarterly Report on Form 10-Q, elsewhere herein and in other filings that we make from time to time with the U.S. Securities and Exchange Commission (the “SEC”). The risks described in such filings are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements.

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and par value data)

	*March 31,*			*December 31,*
	*2026*			*2025*
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	419		$	1,352
Accounts receivable		16			16
Inventory		15			16
Prepaid research and development		18			18
Prepaid expenses and other current assets		405			427
Total current assets		873			1,829
Property, plant and equipment, net		5			6
Right-of-use assets, net		168			195
Long-term prepaid contracts		752			647
Total assets	$	1,798		$	2,677

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	239		$	454
Accrued and other current liabilities		839			532
Deferred revenue		340			252
Insurance premium financing payable		115			183
Operating lease liability		118			113
Total current liabilities		1,651			1,534
Operating lease liability, net of current portion		55			86
Total liabilities		1,706			1,620

Commitments and contingencies (Note 6)

Stockholders’ equity:
Common stock, par value $0.01 per share, 60,000,000 shares authorized; 17,580,744 shares issued and outstanding at each of March 31, 2026 and December 31, 2025		176			176
Additional paid-in capital		108,082			107,450
Accumulated deficit		(108,158	)		(106,557	)
Accumulated other comprehensive loss		(8	)		(12	)
Total stockholders’ equity		92			1,057
Total liabilities and stockholders’ equity	$	1,798		$	2,677

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(in thousands, except share and per share data)

	*Three Months Ended*
	*March 31,*
	*2026*			*2025*
Product revenue	$	226		$	45

Operating expenses:
Cost of sales		206			33
Research and development		563			601
Sales and marketing		18			10
General and administrative		1,045			1,071
Total operating expenses		1,832			1,715

Operating loss		(1,606	)		(1,670	)

Other income (expense), net:
Interest income		2			13
Interest expense		(2	)		(2	)
Other income		5			—
Other income (expense), net		5			11

Net loss	$	(1,601	)	$	(1,659	)

Basic and diluted net loss per share	$	(0.09	)	$	(0.10	)
Weighted average common shares outstanding, basic and diluted		17,580,744			15,918,979

Comprehensive loss:
Net loss	$	(1,601	)	$	(1,659	)
Foreign currency translation adjustments		4			—
Comprehensive loss	$	(1,597	)	$	(1,659	)

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(in thousands, except share data)

	*Number of*									*Accumulated*
	*Common*				*Additional*					*Other*			*Total*
	*Shares*		*Common*		*Paid-in*		*Accumulated*			*Comprehensive*			*Stockholders’*
	*Outstanding*		*Stock*		*Capital*		*Deficit*			*Loss*			*Equity*
Balance at January 1, 2026		17,580,744	$	176	$	107,450	$	(106,557	)	$	(12	)	$	1,057
Share-based compensation expense		—		—		632		—			—			632
Net loss		—		—		—		(1,601	)		—			(1,601	)
Other comprehensive loss		—		—		—		—			4			4
Balance at March 31, 2026		17,580,744	$	176	$	108,082	$	(108,158	)	$	(8	)	$	92

	*Number of*									*Accumulated*
	*Common*				*Additional*					*Other*			*Total*
	*Shares*		*Common*		*Paid-in*		*Accumulated*			*Comprehensive*			*Stockholders’*
	*Outstanding*		*Stock*		*Capital*		*Deficit*			*Loss*			*Equity*
Balance at January 1, 2025		15,918,979	$	159	$	102,757	$	(99,688	)	$	(6	)	$	3,222
Share-based compensation expense		—		—		485		—			—			485
Net loss		—		—		—		(1,659	)		—			(1,659	)
Balance at March 31, 2025		15,918,979	$	159	$	103,242	$	(101,347	)	$	(6	)	$	2,048

See accompanying notes to unaudited condensed consolidated financial statements

Table of Contents

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

	*Three Months Ended*
	*March 31,*
	*2026*			*2025*
OPERATING ACTIVITIES
Net loss	$	(1,601	)	$	(1,659	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense		632			485
Depreciation		1			2
Amortization of operating lease right-of-use assets		27			23
Changes in operating assets and liabilities:
Accounts receivable		—			227
Inventory		1			32
Prepaid expenses and other current assets		22			(85	)
Long-term prepaid contracts		(105	)		70
Accounts payable		(215	)		3
Operating lease liability		(26	)		(22	)
Accrued and other current liabilities		307			(38	)
Deferred revenue		88			299
Insurance premium financing payable		(68	)		(95	)
Net cash used in operating activities		(937	)		(758	)
Effect of exchange rate changes on cash		4			—
Net decrease in cash and cash equivalents		(933	)		(758	)
Cash and cash equivalents at the beginning of the year		1,352			2,486
Cash and cash equivalents at the end of the period	$	419		$	1,728

SUPPLEMENTAL INFORMATION
Interest paid in cash	$	2		$	2

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization

Overview

Harvard Apparatus Regenerative Technology, Inc. (“Harvard Apparatus Regenerative Technology” or the “Company”) is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects. The Company believes its technology is likely to be used to repair wounds or other damage or defects resulting from esophageal cancer, esophageal injuries, and birth defects in the esophagus. The Company believes additional product candidates in its development pipeline may repair wounds or other damage or defects resulting from intestinal cancer and uterus wounds. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets.

Consumer Health Products

The Company’s subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, or Consumer Health Products, focuses on sales of consumer health products.

Consumer Health Products includes a broad range of products focused on personal healthcare including dietary supplements. The Company currently sells dietary supplements through Consumer Health Products. These products are commercially marketed to the general public and initially targeted at consumers in Asia through eCommerce (online sales).

Going Concern

The Company has incurred substantial operating losses since its inception, and as of March 31, 2026, had an accumulated deficit of approximately $108.2 million and will require additional financing to fund future operations. The Company expects that its operating cash on-hand as of March 31, 2026 of approximately $0.4 million and debt financing of $0.5 million in gross proceeds received subsequent to March 31, 2026 will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2026. Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company will need to raise additional capital to fund its current operations. In the event the Company is unable to raise additional capital from outside sources during the second quarter of 2026 , it may be forced to curtail or cease its operations.

Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of product candidates, as well as regulatory efforts and collaborative arrangements necessary for the Company’s product candidates that are currently under development. The Company is currently seeking and will continue to seek financing from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. The Company may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. The Company may not be able to obtain additional financing on favorable terms, if at all.

The Company’s operations will be adversely affected if it is unable to raise or obtain needed funding and may materially affect the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and therefore, the condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty.

Table of Contents

2. Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies

The accounting policies underlying the accompanying condensed consolidated financial statements are those set forth in Note 2 to the condensed consolidated financial statements for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2026 (the “Form 10-K”).

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Harvard Apparatus Regenerative Technology and its subsidiaries; Harvard Apparatus Regenerative Technology Limited (Hong Kong), Harvard Apparatus Regenerative Technology (Hangzhou) Limited (China), Harvard Apparatus Regenerative Technology GmbH (Germany), and Harvard Apparatus Regenerative Technology Incorporated (California). All intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation

The condensed consolidated financial statements reflect the Company’s financial position, results of operations and comprehensive loss and cash flows in conformity with accounting principles generally accepted in the United States, or U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Form 10-K for the fiscal year ended December 31, 2025.

Use of Estimates

The process of preparing condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, share-based compensation, accrued expenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.

Revenue

The Company recognizes revenue in accordance with Financial Accounting Standards Board (“FASB”) ASC 606, Revenue from Contracts with Customers. The Company offers consumer products primarily through a third-party online store. Revenue is recognized at a point in time when control of the goods is transferred to the customer, which generally occurs upon the delivery to the customer. For any company direct sales to customers, revenue is recognized at a point in time upon shipment of product or hand-delivery to customer. In October 2024, the Company entered into an exclusive distribution agreement (the “Distribution Agreement”) with Health Regen, Inc., of Pittsfield, MA (“Health Regen”). Pursuant to the Distribution Agreement, the Company granted Health Regen exclusive distribution rights to all of its Consumer Health Products globally. For any sales to Health Regen, revenue is recognized when goods are made available by the Company for transfer. Revenue also excludes any amounts collected on behalf of third parties, including sales and indirect taxes.

The Company identifies a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on the Company’s financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation.

Table of Contents

Cost of Sales

Cost of sales primarily consists of the purchase price of consumer products, taxes, inbound and outbound shipping costs. Shipping costs to receive products from our suppliers are recognized as cost of sales when incurred. E-commerce processing and related transaction costs, including those associated with seller transactions, are classified in sales and marketing on our condensed consolidated statements of operations and comprehensive loss.

Research and Development

Research and development costs are expensed as incurred.

Sales and Marketing

Sales and marketing costs include advertising and payroll and related expenses for personnel engaged in marketing and selling activities. In October 2024, the Company entered into the Distribution Agreement with Health Regen, pursuant to which the Company granted Health Regen exclusive distribution rights to all of its Consumer Health Products globally. Health Regen primarily facilitates distribution in coordination with the Company’s Hong Kong subsidiary. The initial term of the Distribution Agreement is from November 1, 2024 through December 31, 2030.

General and Administrative

General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses; facilities and equipment expenses, such as depreciation and amortization expense and rent; and professional fees.

Segment Information

The Company manages its operations as two separate operating segments for the purposes of assessing performance and making operating decisions. The Company has one operating unit focused on the development and commercialization of therapies to treat cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The other operating unit is focused on personal healthcare through dietary supplements. The Company has determined that its chief executive officer is the chief operating decision maker (the “CODM”). The CODM reviews separate discrete financial information presented by operating segment. Resource allocation decisions are made by the CODM based on operating segment cash used in operations, revenues and net income (loss).

Cash Concentrations

The Company maintains its cash balances at accredited financial institutions with high credit ratings. These balances are held in federally insured accounts, and from time to time the Company may maintain balances in excess of applicable insurance limits. The Company has not experienced any losses on its cash holdings to date and does not believe it is exposed to significant credit risk beyond the normal risks associated with commercial banking relationships. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation up to $250,000.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company currently invests available cash in money market funds.

Accounts Receivable

Allowances for credit losses are provided for estimated amounts of accounts receivable which may not be collected. At March 31, 2026 and December 31, 2025, we determined that no allowance for credit losses against accounts receivable was necessary. The Company has elected the practical expedient under ASU 2025-05, which assumes current conditions as of the balance sheet date remain unchanged for the remaining life of the asset. Advance payment is required under standard terms.

Table of Contents

Inventory

Inventory, consisting of products available for sale, are primarily accounted for using the first-in, first-out method, and are valued at the lower of cost and net realizable value. This valuation requires us to make judgments, based on currently available information, about the likely method of disposition, such as through sales to individual customers, returns to product vendors, or liquidations, and expected recoverable values of each disposition category.

Long-term Prepaid Contracts

The Company has contracted with partners relating to its clinical trial activities. Upon execution of the contracts, the Company made initial deposits of $1.2 million in connection with a clinical trial contract and will be applied against final invoices which are more than a year away. The deposits will be recorded as expense when the clinical trial is substantially completed. Costs for the clinical trial activities throughout the Company’s clinical trial under these contracts are recognized as expense and payable based on costs incurred. During the three months ended March 31, 2026, the Company paid $0.2 million to replenish the deposit balances which increased the long-term prepaid contracts balance to $0.7 million. In addition to the clinical trial deposits, the Company has $0.1 million in other deposits paid to its landlord as a security deposit and to a university for future esophageal implant production. The other deposits are not expected to be expensed within the next twelve months and are therefore classified as long term.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Leasehold improvements	Shorter of expected useful life or lease term (years)
Computer equipment and software		3
Furniture, machinery and equipment		5 - 7

Maintenance and repairs are charged to expense as incurred, while any additions or improvements are capitalized.

Impairment of Long-Lived Assets

Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, are considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset. Through March 31, 2026, no such impairment charges have been recorded.

Deferred Revenue

The Company does not recognize contract assets, as revenue is not recognized prior to the satisfaction of performance obligations and the right to consideration is unconditional at the time of invoicing. Deferred revenue represents advance payments received from our distributor for goods that will be made available to be transferred in future periods. These payments are initially recorded as liabilities and recognized as revenue when the related goods are provided. The Company had no deferred revenue as of January 1, 2025, as no advance payments from customers were received during that period. Deferred revenue primarily consists of advance payments for consumer health products. The Company expects to recognize this revenue within the next fiscal quarter, as the performance obligations are satisfied.

Management regularly reviews the deferred revenue balance to ensure that revenue is recognized in accordance with the Company’s revenue recognition policy and applicable accounting standards.

The following table summarizes the Company’s contract balances from contracts with customers as required by ASC 606-10-50-8 in thousands:

	March 31,		December 31,
Contract Balances	2026		2025

Deferred revenue	$	340	$	252

Table of Contents

Foreign Currency

Assets and liabilities of non-U.S. operations where the functional currency is other than the U.S. dollar are translated from the functional currency into U.S. dollars at period-end exchange rates, and revenues and expenses are translated at average rates prevailing during the year. Resulting translation adjustments are accumulated as part of accumulated other comprehensive loss. Transaction gains or losses are recognized in income or loss in the period in which they occur.

Net Loss Per Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the if-converted method. For purposes of the diluted net loss per share calculation, warrants to purchase the Company’s common stock, par value $0.01 per share (the “Common Stock”) and stock options are considered to be common stock equivalents, but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.

Concentration of Credit Risk

For the three months ended March 31, 2026 and 2025, Health Regen accounted for approximately 100% and 90% of total product revenue, respectively. Health Regen was the only customer to account for more than 10% of total accounts receivable as of both March 31, 2026 and December 31, 2025.

Unaudited Interim Financial Information

The accompanying interim condensed consolidated balance sheet as of March 31, 2026, condensed consolidated interim statements of operations and comprehensive loss and condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2026 and 2025, and cash flows for the three months ended March 31, 2026 and 2025 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2026, its condensed consolidated results of operations and stockholders’ equity for the three months ended March 31, 2026 and 2025, and cash flows for the three months ended March 31, 2026 and 2025. The financial data and other information disclosed in these notes related to the three months ended March 31, 2026 and 2025 are unaudited. The results for the three months ended March 31, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026, any other interim periods or any future year or period.

Table of Contents

Recent Accounting Pronouncements

Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s condensed consolidated financial statements upon adoption.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 improves disclosures about a public business entity’s expenses by requiring disaggregated disclosures of certain types of expenses, including purchases of inventory, employee compensation, depreciation, intangible amortization and depletion, as applicable, for each income statement caption that includes those expenses. In addition, the standard will require entities to define and disclose total selling expenses. The standard is effective for public business entities for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted, and entities may apply the standard prospectively or retrospectively. The Company is currently evaluating the impact of adopting this standard on its condensed consolidated financial statements and related disclosures.

In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This update provides a practical expedient and an accounting policy election for estimating expected credit losses on current accounts receivable and contract assets arising under ASC 606. The Company adopted ASU 2025-05 effective January 1, 2026, applying the practical expedient, which assumes that current conditions as of the balance sheet date remain unchanged for the remaining life of the asset. The adoption did not have a material impact on the Company's condensed consolidated financial statements.

Fair Value Measurements

There have been no material changes to the Company’s fair value measurement policies, methods, or financial instruments since the disclosures included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

3. Accrued and Other Current Liabilities

Accrued and other current liabilities consist of the following:

	*March 31,*		*December 31,*
	*2026*		*2025*
	(in thousands)
Advisory costs	$	192	$	96
Audit services		59		73
Payroll		588		363
Total accrued and other current liabilities	$	839	$	532

4. Capital Stock

Preferred Stock

The Company has authorized a total of 2,000,000 shares of preferred stock, par value $0.01 per share (the “Preferred Stock”), none of which were outstanding at March 31, 2026 and December 31, 2025. The Company’s Board of Directors (the “Board”) has the authority to issue Preferred Stock and to determine the rights, preferences, privileges, and restrictions, including voting rights.

Common Stock

On December 30, 2025, the Company entered into securities purchase agreements with certain investors each named therein (the “December Investor,” and collectively the “December Investors”) pursuant to which each of the December Investors agreed to purchase in a private placement an aggregate of 411,765 shares of Common Stock for the aggregate gross proceeds of approximately $0.7 million at a purchase price per share of $1.70.

Table of Contents

On July 11, 2025, the Company entered into securities purchase agreements with certain investors each named therein (the “July Investor,” and collectively the “July Investors”) pursuant to which each of the July Investors agreed to purchase in a private placement an aggregate of 1,250,000 shares of Common Stock for the aggregate gross proceeds of approximately $2.0 million at a purchase price per share of $1.60.

Warrants

The Company had 898,622 warrants to purchase Common Stock outstanding as of March 31, 2026 and December 31, 2025 with a weighted-average exercise price of $5.33.

5. Share-Based Compensation

Harvard Apparatus Regenerative Technology Amended and Restated Equity Incentive Plan

The Company maintains the Amended and Restated Equity Incentive Plan, or the Plan, for the benefit of certain officers, employees, non-employee directors, and other key persons (including consultants and advisory board members). All options and awards granted under the Plan consist of shares of Common Stock. The Company’s policy is to issue stock available from its registered but unissued stock pool through its transfer agent to satisfy stock option exercises and the vesting of restricted stock units. The vesting period for awards is generally four years and the contractual life is ten years. Canceled and forfeited options and awards are available to be reissued under the Plan.

As of March 31, 2026, the Company’s Plan has 9,098,000 authorized shares to be issued under the Plan. There were 4,370,364 shares available for issuance as of March 31, 2026.

The following table summarizes information concerning options outstanding and exercisable:

			*Weighted-*		*Weighted-*		*Aggregate*
			*average*		*average*		*intrinsic*
			*exercise*		*contractual*		*value*
	*Amount*		*price*		*life (years)*		*(in thousands)*
Outstanding at December 31, 2025		4,641,685	$	3.72		6.2	$	200
Outstanding at March 31, 2026		4,641,685		3.72		6.0		108
Options exercisable		3,633,843		3.63		5.9		105
Options vested and expected to vest		4,620,139		3.71		6.0		108

Total unrecognized compensation expense for the remaining 860,729 performance-based awards is approximately $3.1 million as of March 31, 2026.

As of March 31, 2026, a performance condition associated with certain performance-based awards was determined to be probable of achievement. As a result, the Company recognized $194,870 of share-based compensation expense during the quarter related to these awards, representing the cumulative expense recognized based on the updated probability assessment in accordance with ASC 718. The Company recognized approximately $0.2 million and $0.02 million in share-based compensation during the three months ended March 31, 2026 and 2025, respectively.

Aggregate intrinsic value for outstanding options as of March 31, 2026 was approximately $0.1 million and was calculated as the difference between the Company’s closing stock price of $1.68 per share as of March 31, 2026 and the weighted average exercise price of $3.72. As of March 31, 2026, unrecognized compensation cost related to unvested non-performance-based awards amounted to $0.3 million, which will be recognized over a weighted-average period of 0.9 years.

Table of Contents

The Company recorded share-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:

	*Three Months Ended*
	*March 31,*
	*2026*		*2025*
	(In thousands)
Research and development	$	169	$	59
General and administrative		463		426
Total	$	632	$	485

6. Commitments and Contingencies

From time to time, the Company may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that the Company expects to be material in relation to its business, financial condition, results of operations, or cash flows.

On August 12, 2024, the Company entered into an operating lease agreement for approximately 10,629 square feet of office, research and development and light manufacturing space located in Holliston, MA (the “HQ Lease”). The space will continue to serve as the Company’s corporate headquarters and manufacturing facility. The term of the HQ lease ends on August 31, 2027.

In April 2025, the Company entered into a Master Service Agreement with uBriGene (Boston) Biosciences, Inc., a contract development and manufacturing organization, pursuant to which uBriGene will provide development, manufacturing, and related regulatory support services for the Company’s investigational programs. Services are performed under statements of work and are milestone‑based. Under the applicable statement of work, contractual milestones include: (i) execution of the agreement and initiation of technology transfer activities; (ii) completion of multiple technology transfer production runs and related quality control testing; (iii) completion of stability testing using materials produced from the technology transfer runs; (iv) initiation of investigational batch production; and (v) completion of investigational batch production and associated regulatory support activities. Fees are payable upon the achievement of these milestones. The Company may terminate the agreement or any statement of work upon prior written notice. Upon termination, the Company is not obligated to pay for services not performed prior to the effective date of termination but remains responsible for amounts incurred for services performed and certain non‑cancelable costs. Payments made in advance of services being rendered are recorded as prepaid expenses and expensed as the related services are performed.

As of March 31, 2026, the Company had no minimum remaining non‑cancelable purchase commitments under this agreement, as all future payments are contingent upon the achievement of development and manufacturing milestones and the Company’s authorization of continued services.

On July 1, 2025, the Company entered into a services agreement with Beijing Quarkmed Technology Co., Ltd. with a total contract value of approximately $206,000 for regulatory and clinical support activities. In the third quarter of 2025, the Company made an initial payment of $72,118.44, which was fully expensed by December 31, 2025 using a percentage‑of‑completion method. No additional payments had been made under the contract as of March 31, 2026. As of March 31, 2026, the Company had incurred approximately $93,000 of costs, all of which are included in research and development expense. Accordingly, no prepaid assets related to this agreement were recorded as of March 31, 2026.

In November 2025, the Company entered into an insurance premium financing and security agreement. Under the agreement, the Company financed $228,685 of certain premiums at a 7.60% annual interest rate. As of March 31, 2026, the outstanding balance on the financing and security agreement was $114,648 and is included on the balance sheet in insurance premium financing payable. The final payment is due in August 2026.

Table of Contents

7. Leases

The Company leases laboratory and office space and certain equipment with a remaining term of one year.

On August 12, 2024, the Company entered into the HQ Lease, an operating lease agreement for laboratory and office space in Holliston, MA, with an initial three-year term from September 1, 2024 through August 31, 2027. The Company accounts for the HQ Lease in accordance with ASC Topic 842, Leases. The Company recorded approximately $323,000 as a right-of-use asset and a corresponding operating lease liability on the Company’s condensed consolidated balance sheets upon the accounting commencement date on September 1, 2024. The lease liability was measured at the accounting commencement date utilizing a 13.3% discount rate.

The HQ Lease contains escalating payments during the lease term. Upon execution of the HQ Lease, the Company paid a security deposit, which will be held in escrow and credited at the termination of the lease. As of March 31, 2026, a security deposit of approximately $14,000 was included in long-term prepaid contracts on the Company’s condensed consolidated balance sheet related to the HQ Lease.

All of the Company’s leases qualify as operating leases. The following table summarizes the presentation of the Company’s operating leases in its condensed consolidated balance sheets:

		*March 31,*		*December 31,*
	*Balance Sheet Classification*	*2026*		*2025*

Assets:
Operating lease assets	Right-of-use assets, net	$	168	$	195
Liabilities:
Current portion of operating lease liability	Current portion of operating lease liability		118		113
Operating lease liability, net of current portion	Operating lease liability, net of current portion		55		86
Total operating lease liability		$	173	$	199

The Company recorded operating lease expense in the following categories in its condensed consolidated statements of operations and comprehensive loss:

	*Three Months Ended*
	*March 31,*
	*2026*		*2025*
	(in thousands)
Research and development	$	22	$	20
General and administrative		11		13
Total	$	33	$	33

Table of Contents

Cash paid included in the computation of the operating lease assets and lease liability during the three months ended March 31, 2026 and 2025 amounted to approximately $33,000 and $32,000, respectively.

The weighted average remaining lease term and weighted average discount rate of the Company’s operating leases are as follows:

	*As of March 31,*
	*2026*			*2025*
Remaining lease term (in years)		1.42			2.42
Discount rate		13.29	%		13.29	%

The minimum lease payments for future years are as follows:

	*As of*
	*March 31,*
	*2026*
	(in thousands)
2026	$	100
2027		90
Total lease payments		190
Less: imputed interest		(17	)
Present value of operating lease liability	$	173

8. Net Loss Per Share

The following potential common shares were excluded from the calculation of diluted net loss per share attributable to common stockholders for the three months ended March 31, 2026 and 2025 because including them would have had an anti-dilutive effect:

	*Three Months Ended*
	*March 31,*
	*2026*		*2025*
Options to purchase Common Stock		4,641,685		4,385,477
Warrants to purchase Common Stock		898,622		898,622
Total		5,540,307		5,284,099

9. Income Taxes

The Company did not record a federal or state income tax provision or benefit for the three months ended March 31, 2026 and 2025, respectively, due to the expected loss before income taxes to be incurred for the years ended December 31, 2026 and 2025, as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets.

10. Segments

The Company’s CODM is its Chief Executive Officer. The Company’s CODM evaluates the operating results of the Company’s reportable segments based on cash used in operations, revenues and net loss.

The Company follows the accounting guidance of ASC 280, Segment Reporting (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the CODM organizes the segments within an enterprise for making operating decisions and assessing performance. While the Company’s results of operations are primarily reviewed on a consolidated basis, the CODM manages the enterprise in two reportable segments, each with different operating and potential revenue generating characteristics.

Table of Contents

The Company has two operating and reportable segments: (i) Regenerative Biotech focused on the development of regenerative medicine treatments with operations currently in the United States and (ii) Consumer Health Products relating to consumer health products with operations currently in Asia. All of the Company’s revenue was generated in Asia for the three months ended March 31, 2026 and 2025. The following tables present segment revenues, significant expense categories provided to the Company’s CODM at least quarterly, other segment items, and net loss for the three months ended March 31, 2026 and 2025, in thousands:

Three Months Ended March 31, 2026
	Regenerative Biotech			Consumer Health Products		Consolidated Total
*Revenue*
Product revenue	$	—		$	226	$	226
*Significant Expense Categories (provided to CODM)*
Cost of sales		—			206		206
Research and development		563			—		563
Sales and marketing		2			16		18
General and administrative (a)		1,044			1		1,045
Total significant segment expenses		1,609			223		1,832
*Other Segment Items*
Other segment items (b)		5			—		5
Segment net loss	$	(1,604	)	$	3	$	(1,601	)

Three Months Ended March 31, 2025
	Regenerative Biotech			Consumer Health Products		Consolidated Total
*Revenue*
Product revenue	$	—		$	45	$	45
*Significant Expense Categories (provided to CODM)*
Cost of sales		—			33		33
Research and development		601			—		601
Sales and marketing		8			2		10
General and administrative (a)		1,071			—		1,071
Total significant segment expenses		1,680			35		1,715
*Other Segment Items*
Other segment items (b)		11			—		11
Segment net loss	$	(1,669	)	$	10	$	(1,659	)

Table of Contents

The following table presents cash and cash equivalents and total assets by segment as of March 31, 2026 and December 31, 2025, in thousands:

	*March 31,*		*December 31,*
	*2026*		*2025*
Cash and cash equivalents:
Regenerative Biotech	$	127	$	1,206
Consumer Health Products		292		146
Total	$	419	$	1,352

Total assets:
Regenerative Biotech	$	1,225	$	2,277
Consumer Health Products		573		400
Total	$	1,798	$	2,677

(a) Certain general and administrative costs (including executive compensation, corporate legal fees, audit fees, investor relations, and insurance) are shared across both segments. For internal reporting purposes, such costs are allocated to each segment based on an estimate of the proportion of management time and corporate resources utilized by each segment. Costs directly attributable to a segment are charged directly to that segment. For the three months ended March 31, 2026 and 2025, the Regenerative Biotech segment bore substantially all general and administrative expense, as the Consumer Health Products segment incurred minimal shared corporate overhead.

(b) “Other segment items” for the Regenerative Biotech segment consists primarily of net interest income earned on money market balances and other miscellaneous income, partially offset by interest expense on insurance premium financing. For the Consumer Health Products segment, other segment items consist of foreign currency transaction effects and other minor income items. The other segment items line represents the arithmetic difference between segment revenues, less the significant expense categories disclosed above, and the reported segment net loss, in accordance with ASC 280-10-50-26B.

11. Subsequent Events

On April 13, 2026 and on May 8, 2026, the Company entered into loan arrangements with Junli He, the Chairman, Chief Executive Officer, and Director of the Company (the “Lender”), pursuant to which the Lender has agreed to loan the Company an aggregate amount of $500,000 as evidenced by a Bridge Note executed by the Company in favor of, and accepted by, the Lender (the “Bridge Note”).

The Bridge Note accrues interest at an annual fixed rate of 8%, and the principal amount thereof will be due and payable in full, together with all accrued and unpaid interest thereon, on the earlier to occur of a) the closing date (or later date of capital being provided pertaining to such continued offering that the following threshold is tripped) of the Company’s next capital raise that includes gross proceeds of at least $5,000,000 or b) maturity date. The Bridge Note provides for optional conversion at the discretion of the Lender, contains covenants, and provides for certain events of default including if the Company fails to pay when due any amount owed thereunder, fails to comply with any agreement, covenant, condition, provision or term contained therein and other customary events of default.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

The following section of this Quarterly Report on Form 10-Q entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains statements that are not statements of historical fact and are forward-looking statements within the meaning of federal securities laws. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties.

In some cases, you can identify forward-looking statements by terms such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “could,” “would,” “target,” “seek,” “aim,” “predicts,” “think,” “objectives,” “optimistic,” “new,” “goal,” “strategy,” “potential,” “likely,” “will,” “expect,” “plan,” “project,” “permit” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on March 19, 2026. You should carefully review all of these factors, as well as the comprehensive discussion of forward-looking statements on page 3 of this Quarterly Report on Form 10-Q.

Harvard Apparatus Regenerative Technology, Inc. is referred to herein as “we,” “our,” “us”, and “the Company”.

Business Overview

We are a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects.

Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrificing of another of the patient’s own organs or permanent artificial implants.

Our first esophageal product candidate, our esophageal implant, was used in the first successful regeneration of the esophagus in a patient with esophageal cancer. This successful first-in-human experience, plus the research we have performed on over 50 pigs, led the FDA to approve our 10-patient Phase 1 clinical trial. This combination trial will measure both safety and efficacy in the patient population.

We have contracted with IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (“CRO”) to manage our first clinical trial. We activated the first clinical trial site and started screening patients in the third quarter of 2023.

We have encountered delays in patient recruitment for our ongoing clinical trial, driven by several factors, including the existing comorbid conditions for clinical trial participants, the stringent eligibility criteria required by FDA for our studies, and logistical difficulties in enrolling participants across various sites.

Although we are actively implementing strategies to mitigate these challenges, such as increasing the number of trial sites and enhancing patient outreach efforts, there is a risk that these measures may not completely resolve the recruitment issues. Our product candidates are currently in development and have not yet received regulatory approval for sale anywhere in the world.

In addition to our development of regenerative medicine treatments, we also sell dietary supplements. Our subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, or Consumer Health Products, focuses on sales of consumer health products. Consumer Health Products plans to include a broad range of products focused on personal healthcare including dietary supplements. These products are commercially marketed to the general public and initially targeted at consumers in Asia through eCommerce (online sales).

Table of Contents

We were incorporated and commenced operations on November 1, 2013 as a result of a spin-off from Harvard Bioscience, Inc., or Harvard Bioscience. On that date, we became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution of all the shares of common stock of Harvard Apparatus Regenerative Technology to Harvard Bioscience stockholders.

We continue to assess the market and regulatory approval pathway in China as to our implant products. We are not certain at this time as to which market, including U.S. or China for example, may provide the most viable initial pathway for regulatory approval to a commercial product. This will depend on a number of factors, including the approval and development processes, related costs, ability to raise capital and the terms and conditions thereof, among other factors. Any development and capital raising efforts in China may include a joint venture in relation to our Hong Kong subsidiary, and would also involve a number of commercial variables, including rights and obligations pertaining to licensing, development, and financing, among others. Our failure to receive or obtain such clearances or approvals on a timely basis or at all, whether that be in the U.S., China or otherwise, would have an adverse effect on our results of operations.

Since our incorporation, we have devoted substantially all of our resources to developing our programs, building our intellectual property portfolio, business planning, raising capital and providing selling, general and administrative support for these operations. To date, we have financed our operations with proceeds from the sales of Common Stock, Preferred Stock and warrants.

Business Segments

We have two separate reportable segments. One segment, Harvard Apparatus Regenerative Technology, Inc., or Regenerative Biotech, is focused on the development and commercialization of therapies to treat cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The other segment, Consumer Health Products, is focused on personal healthcare, including dietary supplements.

Financial Condition and Need for Additional Funds

We expect to continue to incur operating losses and negative cash flows from operations during 2026 and in future years.

Operating Losses and Cash Requirements

We have incurred substantial operating losses since our inception, and as of March 31, 2026, had an accumulated deficit of approximately $108.2 million and will require additional financing to fund future operations. We expect that our operating cash on-hand as of March 31, 2026 of approximately $0.4 million and debt financing of $0.5 million in gross proceeds received subsequent to March 31, 2026 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2026. We expect to continue to incur operating losses and negative cash flows from operations for 2026 and in future years. Therefore, as disclosed in Note 1 to our Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q, these conditions raise substantial doubt about our ability to continue as a going concern.

We will need to raise additional capital to fund our current operations. In the event we do not raise additional capital from outside sources during the second quarter of 2026, we may be forced to curtail or cease our operations.

Table of Contents

Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of product candidates, as well as regulatory efforts and collaborative arrangements necessary for our product candidates that are currently under development. We are currently seeking and will continue to seek financings from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. We may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. We may not be able to obtain additional financing on favorable terms, if at all.

Our operations will be adversely affected if we are unable to raise or obtain needed funding and may materially affect our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and therefore, the condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty.

Components of Operating Loss

Product revenue. Product revenue consists of consumer health product sales in the Asia region.

Research and development expense. Research and development expense consists of salaries and related expenses, including share-based compensation, for personnel and contracted consultants and various materials and other costs to develop our new products, primarily: synthetic scaffolds, including investigation and development of materials and investigation and optimization of cellularization, as well as studies of cells and cell behavior. Other research and development expenses include the costs of outside service providers and material costs for prototype and test units and outside laboratories and testing facilities performing cell growth and materials experiments, as well as the costs of all other preclinical research and testing including animal studies and expenses related to potential patents. We expense research and development costs as incurred.

Sales and marketing expense. Sales and marketing costs include advertising and payroll and related expenses for personnel engaged in marketing and selling activities.

General and administrative expense. Selling, general and administrative expense consists primarily of salaries and other related expenses, including share-based compensation. Other costs include professional fees for legal and accounting services, insurance, investor relations and facility costs.

Other income (expense), net. Other income (expense), net, consists primarily of finance charges on insurance installment payments offset by interest income.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.

While our significant accounting policies are discussed in more detail in Note 2 to our Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.

Table of Contents

Share-based Compensation

We account for our share-based compensation in accordance with the fair value recognition provisions of current authoritative guidance. Share-based awards, including stock options, are measured at fair value as of the grant date and recognized as expense over the requisite service period (generally the vesting period), which we have elected to amortize on a straight-line basis. Expense on share-based awards for which vesting is performance or milestone based is recognized on a straight-line basis from the date when we determine the achievement of the milestone is probable to the vesting/milestone achievement date. Since share-based compensation expense is based on awards ultimately expected to vest, it has been reduced by an estimate for future forfeitures. We account for forfeitures as they occur. We estimate the fair value of options granted using the Black-Scholes option valuation model. Significant judgment is required in determining the proper assumptions used in this model. The assumptions used include the risk-free interest rate, expected term, expected volatility, and expected dividend yield. We base our assumptions on historical data when available or, when not available, on a peer group of companies. However, these assumptions consist of estimates of future market conditions, which are inherently uncertain and subject to our judgment, and therefore any changes in assumptions could significantly impact the future grant date fair value of share-based awards.

Results of Operations

The following table summarizes the results of our operations for the three months ended March 31, 2026 and 2025 (in thousands):

	Three Months
	Ended						Change 2026
	March 31,						vs. 2025
	2026			2025			Change			%
Product revenue	$	226		$	45		$	181			402	%

Operating expenses
Cost of sales		206			33			173			524	%
Research and development		563			601			(38	)		(6	%)
Sales and marketing		18			10			8			80	%
General and administrative		1,045			1,071			(26	)		(2	%)
Total operating expenses		1,832			1,715			117			7	%

Other income (expense), net:
Interest income		2			13			(11	)		(85	%)
Interest expense		(2	)		(2	)		—			0	%
Other income		5			—			5			100	%
Total other income, net		5			11			(6	)		(55	%)
*Net loss*	$	(1,601	)	$	(1,659	)	$	58			(3	%)

Table of Contents

Comparison of the three months ended March 31, 2026 and 2025

Product Revenue

Product revenue was $226,000 and $45,000 for the three months ended March 31, 2026 and 2025, respectively. The $181,000 increase, representing a 402% growth, was driven by expanded distribution and new product launches within our Consumer Health segment, including CoQ-10 and sleep aid gummies, alongside continued strong performance from our existing offerings such as Liver Guard.

Cost of Sales

Cost of sales was $206,000 and $33,000 for the three months ended March 31, 2026 and 2025, respectively. The increase reflects scaling of operations to match higher sales.

Research and Development Expense

Research and development expense decreased approximately 6%, to approximately $0.56 million for the three months ended March 31, 2026 as compared to approximately $0.60 million for the three months ended March 31, 2025. This decrease was primarily reflecting lower preclinical spend.

Sales and Marketing Expense

Selling and marketing expense increased approximately 80%, to approximately $18,000 for the three months ended March 31, 2026 as compared to approximately $10,000 the three months ended March 31, 2025 This increase included advertising and promotional costs.

General and Administrative Expense

General and administrative expense decreased approximately 2%, to approximately $1.0 million for the three months ended March 31, 2026 as compared to approximately $1.1 million for the three months ended March 31, 2025. This decrease is mainly due to one-time employee related costs in the prior period.

Interest income

During the three months ended March 31, 2026 and 2025, we recorded interest income of approximately $2,000 and $13,000, respectively, earned from our money market account.

Interest expense

During the three months ended March 31, 2026 and 2025 we recorded interest expense of approximately $2,000 on insurance installment payments.

Other income

For the three months ended March 31, 2026, we recorded approximately $5,000 in other income from sublease activity. These activities are part of our ongoing efforts to optimize the use of our facilities and engage with stakeholders.

Liquidity and Capital Resources

Sources of liquidity. We have incurred operating losses since inception, and as of March 31, 2026, we had an accumulated deficit of approximately $108.2 million. We are currently investing significant resources in the development and commercialization of our product candidates for use by clinicians and researchers in the fields of regenerative medicine and bioengineering. As a result, we expect to incur operating losses and negative operating cash flows for the foreseeable future. Therefore, as disclosed in Note 1 to our Condensed Consolidated Financial Statements, these conditions raise substantial doubt about our ability to continue as a going concern.

Table of Contents

The following table sets forth the primary uses of cash for the three months ended March 31, 2026 and 2025 (in thousands):

	Three Months Ended
	March 31,
	2026			2025
Net cash used in operating activities	$	(937	)	$	(758	)

Comparison of the three months ended March 31, 2026 and 2025

Operating activities. Net cash used in operating activities of approximately $0.9 million for the three months ended March 31, 2026 was due primarily to our net loss of approximately $1.6 million offset by adjustments for non-cash items of approximately $0.7 million due to non-cash expenses for share-based compensation, depreciation and amortization, and a negligible change to cash from changes in working capital due to the timing of payments for accounts receivable, inventory, prepaid expenses, long-term prepaid contracts, accounts payable, deferred revenue and accrued expenses.

Net cash used in operating activities of approximately $0.8 million for the three months ended March 31, 2025 was due primarily to our net loss of approximately $1.7 million offset by adjustments for non-cash items of approximately $0.5 million due to non-cash expenses for share-based compensation, depreciation and amortization, and an approximately $0.4 million increase to cash from changes in working capital due to the timing of payments for accounts receivable, inventory, prepaid expenses, deferred financing costs, long-term prepaid contracts, accounts payable and accrued expenses.

Off-Balance Sheet Arrangements

We do not have any material off-balance sheet arrangements as of March 31, 2026.

Other Information

None.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The Company is a smaller reporting company and is not required to provide this information pursuant to Item 305(e), Regulation S-K.

Item 4. Controls and Procedures.

This Report includes the certifications of our principal executive officer and our principal financial and accounting officer required by Rule 13a-14 of the Exchange Act. See Exhibits 31.1 and 31.2.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chairman, who is our principal executive officer, and our Chief Financial Officer, who is our principal financial and accounting officer, to allow timely decisions regarding required disclosures.

In connection with the preparation of this Quarterly Report on Form 10-Q, our management, under the supervision and with the participation of our principal executive officer and our principal financial and accounting officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2026. Based upon the evaluation described above, our principal executive officer and our principal financial and accounting officer have concluded that they believe our disclosure controls and procedures were effective as of the end of the period covered by this report, in providing reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial and accounting officer, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

Changes in Internal Control over Financial Reporting

Our management, with the participation of our principal executive officer and our principal financial and accounting officer, has evaluated whether any change in our internal control over financial accounting and reporting occurred during the quarter ended March 31, 2026. During the period covered by this report, we have concluded that there were no changes during the fiscal quarter in our internal control over financial reporting, as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act, which have materially affected, or are reasonably likely to materially affect, our internal control over financial accounting and reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that we expect to be material in relation to our business, financial condition, and results of operations or cash flows.

Item 1A. Risk Factors

To our knowledge and except to the extent additional factual information disclosed in this Quarterly Report on Form 10-Q relates to such risk factors, there have been no material changes in the risk factors described in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 19, 2026.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 5. Other Information

During the three months ended March 31, 2026, no directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

Exhibit Index

31.1*		Certification of Chief Executive Officer, Director, and Chairman of Harvard Apparatus Regenerative Technology, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Chief Financial Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of Chief Executive Officer, Director, and Chairman of Harvard Apparatus Regenerative Technology, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of Chief Financial Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		Inline XBRL Taxonomy Extension Schema Document.

Table of Contents

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

Exhibit 104		Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

*	Filed herewith.

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by undersigned thereunto duly authorized.

Date: May 11, 2026

	HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.

	By:	/s/ Junli He
	Name:	Junli He
	Title:	Chief Executive Officer, Director, and Chairman (principal executive officer)

	By:	/s/ Joseph L.Damasio Jr.
	Name:	Joseph L. Damasio Jr.
	Title:	Chief Financial Officer (principal financial and accounting officer)

Harvard Apparatus Regenerative Technology, Inc. 10-Q